Osei-Safo, D.Agbonon, A.Konadu, D.Y.Harrison, J.J.E.K.Edoh, M.Gordon, A.Gbeassor, M.Addae-Mensah, I.2015-06-252017-10-142015-06-252017-10-142014http://197.255.68.203/handle/123456789/6338This study, conducted as part of our overall goal of regular pharmacovigilance of antimalarial medicines, reports on the quality of 132 artemisinin-based antimalarial medicines distributed in Ghana and Togo. Three methods were employed in the quality evaluation – Basic (colorimetric) Tests for establishing the identity of the requisite Active Pharmaceutical Ingredients (APIs), semi-quantitative TLC assay for the identification and estimation of API content and HPLC assay for a more accurate quantification of API content. From the basic tests, only one sample totally lacked API. The HPLC assay, however, showed that 83.7% of the ACTs and 57.9% of the artemisinin-based monotherapies failed to comply with International Pharmacopoeia requirements due to insufficient API content. In most of the ACTs, the artemisinin component was usually the insufficient API. Generally, there was a good correlation between the HPLC and SQ-TLC assays. The overall failure rates for both locally-manufactured (77.3%) and imported medicines (77.5%) were comparable. Similarly the unregistered medicines recorded a slightly higher overall failure rate (84.7%) than registered medicines (70.8%). Only two instances of possible cross-border exchange of medicines were observed and there was little difference between the medicine quality of collections from border towns and those from inland parts of both countries.Artemisinin-based Combination TherapiesQualitySubstandardBasic TestsSemi-quantitative Thin-Layer ChromatographyHigh Pressure Liquid ChromatographyArticle